Anti-viral pharmaceutical compositions
The present invention provides antiviral compositions that comprise one or more of an ionic multivalent metal component, a cationic polymer, and a cationic surfactant. The present invention also provides methods for making and using such antiviral compositions.
1. An antiviral composition comprising chitosan, a cationic surfactant, and water, wherein
the concentration of chitosan is about 0.1% to about 5% (w/w);
the concentration of cationic surfactant is about 0.01% to about 1% (w/w), wherein the cationic surfactant is benzalkonium chloride; and
the composition is for use in ameliorating an infection by a virus selected from the group consisting of influenzavirus, rhinovirus, adenovirus, coronavirus, parainfluenzavirus, respiratory syncytical virus, and herpes virus, wherein the composition does not contain zinc.
2. The composition of claim 1 , wherein the cationic surfactant is benzalkonium chloride.
3. The composition of claim 1 , wherein the concentration of chitosan is about 2% (w/w).
4. The composition of claim 1 , wherein the concentration of the cationic surfactant is about 0.02% (w/w).
5. The composition of claim 1 , wherein the chitosan is in a concentration of 0.1% (w/w), and the benzalkonium chloride is in a concentration of 1% (w/w).
6. The composition of claim 1 , wherein the composition optionally comprises one or more members selected from the group consisting of a pH adjusting agent, a pH buffer, a viscosity modifier, an osmotic agent, a flavor, a sweetener, a preservative, an adhesive, and a colorant.
7. The composition of claim 1 , further comprising a pharmaceutically acceptable excipient, wherein the composition is formulated for local administration.
8. The composition of claim 1 , formulated as a member selected from the group consisting of a solution, a paste, a gel, a suspension, a lotion, a cream, an aerosol, a dressing, a bandage, a lacquer, and an ointment.
9. The composition of claim 1 , wherein the composition is for administration as a nasal spray.
10. The composition of claim 1 , wherein
the concentration of chitosan is 1.5% (w/w);and
the cationic surfactant is benzalkonium chloride.
11. A method for ameliorating a viral infection caused by a virus selected from the group consisting of influenzavirus, rhinovirus, adenovirus, coronavirus, parainfluenzavirus, respiratory syncytical virus, and herpes virus, said method comprising administering to a subject in need thereof a composition of claim 1 .
12. The method of claim 11 , wherein the viral infection is caused by an influenza virus.
13. The method of claim 11 , wherein
the concentration of chitosan in the composition is 1.5% (w/w); and
the concentration of cationic surfactant is about 0.01% to about 1% (w/w), wherein the cationic surfactant is benzalkonium chloride.
14. The method of claim 13 , wherein the cationic surfactant is benzalkonium chloride.
15. The method of claim 11 , wherein the concentration of chitosan is about 0.1% (w/w).
16. The method of claim 13 , wherein the concentration of the cationic surfactant is about 0.1% (w/w).